Article
Medicine, General & Internal
M. R. Mirza, D. M. Chase, B. M. Slomovitz, R. dePont Christensen, Z. Novak, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L. M. Landrum, L. C. Hanker, A. Stuckey, I. Boere, M. A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M. S. Shahin, S. E. Gill, B. J. Monk, J. Buscema, T. J. Herzog, L. J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R. L. Coleman, M. A. Powell
Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
V Makker, N. Colombo, A. Casado Herraez, A. D. Santin, E. Colomba, D. S. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I Ray-Coquard, R. Shapira-Frommer, K. Ushijima, J. Sakata, K. Yonemori, Y. M. Kim, E. M. Guerra, U. A. Sanli, M. M. McCormack, A. D. Smith, S. Keefe, S. Bird, L. Dutta, R. J. Orlowski, D. Lorusso
Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Laura M. Chambers, Xuefei Jia, Peter G. Rose, Mariam AlHilli
Summary: Based on analysis from the National Cancer Database (NCDB) from 2004 to 2015, the study found that primary cytoreductive surgery and chemotherapy (PCS + CT) is associated with improved overall survival (OS) compared to neoadjuvant chemotherapy and interval debulking surgery (NACT + IDS) and chemotherapy alone (CT) in women with advanced endometrial cancer.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Medicine, General & Internal
Amy McCarthy, Katharine Balfour, Iman El Sayed, Richard Edmondson, Yee-Loi Louise Wan
Summary: There is no consensus on optimal treatment for advanced endometrial cancer, with neoadjuvant therapies like chemotherapy and radiotherapy being used to improve surgical outcomes. This review aims to assess whether neoadjuvant therapy improves health outcomes compared to upfront surgery in advanced endometrial cancer patients. Data will be collected and analyzed using PRISMA guidelines, with findings disseminated through peer-reviewed publications and practice guidelines updates.
Article
Oncology
Leila T. Tchelebi, Cathy Eng, Craig A. Messick, Theodore S. Hong, Ethan B. Ludmir, Lisa A. Kachnic, Nicholas G. Zaorsky
Summary: The treatment of squamous cell carcinoma of the anus has shifted from radical surgery to sphincter-preserving chemoradiation, with chemotherapy using mitomycin-C and 5-fluorouracil found to be essential for cure. Advanced radiation techniques are now considered standard of care, and further studies are exploring the addition of immune checkpoint inhibitors in locally advanced cancers.
CA-A CANCER JOURNAL FOR CLINICIANS
(2022)
Review
Oncology
Francesca Tronconi, Camilla Nero, Elena Giudice, Vanda Salutari, Lucia Musacchio, Caterina Ricci, Maria Vittoria Carbone, Viola Ghizzoni, Maria Teresa Perri, Floriana Camarda, Marica Gentile, Rossana Berardi, Giovanni Scambia, Domenica Lorusso
Summary: Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and limited treatment options. Platinum-based chemotherapy is currently the main treatment. Recent approvals have been granted for combination therapies, but predictive biomarkers are lacking to identify patients who are most likely to benefit.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Sachin R. Jhawar, Marcelo Bonomi, Paul M. Harari
Summary: The Oncology Grand Rounds series aims to help readers apply the results of key studies in clinical practice, using case presentations, literature reviews, and treatment recommendations to enhance understanding of the latest developments in oncology.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Angiolo Gadducci, Stefania Cosio
Summary: Patients with metastatic or recurrent endometrial cancer who are not suitable for surgery and/or radiotherapy often have unsatisfactory clinical outcomes with pharmacological treatment. The combination of carboplatin + paclitaxel is the standard first-line chemotherapy, while hormonal therapy is sometimes used for steroid receptor-positive EC patients. Immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, have shown good objective responses in highly pretreated patients with MMR-deficient EC.
Article
Obstetrics & Gynecology
Yuanyuan Zhang, Yi Huang, Suiyu Luo, Lin Li, Hongying Yang, Ziyi Wang, Yongmei Peng, Manni Huang, Jusheng An, Xi Yang, Jing Wang, Chunmei Li, Lingying Wu
Summary: This study analyzed the management of high-grade neuroendocrine cervical cancer (HGNECC) and found that chemotherapy was the preferred treatment, improving progression-free survival (PFS) and overall survival (OS). Distance metastasis was a negative prognostic factor for OS, while radical surgery was a positive prognostic factor for PFS. Comparing different chemotherapy regimens, paclitaxel plus platinum-based chemotherapy showed better outcomes than cisplatin and etoposide. Radical surgery followed by chemotherapy may be a favorable alternative intervention for selected patients.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
(2022)
Article
Oncology
Hyunji Lim, Seung Hyun Bang, Yeorae Kim, Sang Hyun Cho, Wonkyo Shin, Se Ik Kim, Tae Hun Kim, Dong Hoon Suh, Myong Cheol Lim, Jae-Weon Kim
Summary: The study aimed to assess the feasibility and effectiveness of neoadjuvant chemotherapy followed by interval debulking surgery (NAC-IDS) in unresectable, metastatic endometrial cancer. The results suggest that NAC-IDS may be a treatment option, with tumor histology and the possibility of complete cytoreduction as the primary considerations.
Article
Oncology
Maria Gebre-Medhin, Eva Brun, Per Engstrom, Hedda Haugen Cange, Lalle Hammarstedt-Nordenvall, Johan Reizenstein, Jan Nyman, Edvard Abel, Signe Friesland, Helena Sjodin, Henrik Carlsson, Karin Soderkvist, Marcus Thomasson, Bjorn Zackrisson, Per Nilsson
Summary: The study demonstrates that for patients with locoregionally advanced HNSCC, cisplatin is superior to cetuximab in terms of locoregional control when used in combination with radiotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Aditi Bhatt, Praveen Kammar, Snita Sinukumar, Loma Parikh, Nutan Jumle, Sakina Shaikh, Sanket Mehta
Summary: Total parietal peritonectomy (TPP) can improve survival of patients with advanced serous epithelial ovarian cancer undergoing interval cytoreductive surgery (CRS). This report presents morbidity outcomes for the first 50 patients enrolled in the prospective study TORPEDO (CTRI/2018/12/016789), showing acceptable complications and mortality rates, as well as microscopic disease in 'normal appearing' peritoneum.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Muhyi Al-Sarraf, Michel Leblanc, P. G. Shanker Giri, Karen K. Fu, Jay Cooper, Te Vuong, Arlene A. Forastiere, George Adams, Wael A. Sakr, David E. Schuller, John F. Ensley
Summary: This study aimed to compare the effects of chemoradiotherapy with radiotherapy alone in patients with nasopharyngeal cancers. The results showed that the progression-free survival and overall survival were better in the chemoradiotherapy group. We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Jiayi Guo, Siqi Li, Yuping Wu
Summary: This study aims to examine the efficacy and safety of adjuvant chemotherapy alone in patients with advanced endometrial carcinoma through a systematic review and meta-analysis. Patients with advanced endometrial cancer will benefit from this research.
Article
Multidisciplinary Sciences
Zhaoqing Tang, Yan Wang, Dan Liu, Xuefei Wang, Chen Xu, Yiyi Yu, Yuehong Cui, Cheng Tang, Qian Li, Jing Sun, Qian Zhang, Yuan Ji, Guifen Ma, Haojie Li, Zhenbin Shen, Kuntang Shen, Rongrong Zheng, Zhiguo Hou, Tianshu Liu, Jiping Wang, Yihong Sun
Summary: Neoadjuvant camrelizumab plus concurrent chemoradiotherapy shows promising pathological response in patients with locally advanced gastric adenocarcinoma, with an acceptable safety profile.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Abigail D. Winder, Kruti P. Maniar, Jian-Jun Wei, Dachao Liu, Denise M. Scholtens, John R. Lurain, Julian C. Schink, Barbara M. Buttin, Virginia L. Filiaci, Heather A. Lankes, Nilsa C. Ramirez, Kay Park, Meenakshi Singh, Richard W. Lieberman, Robert S. Mannel, Matthew A. Powell, Floor J. Backes, Cara A. Mathews, Michael L. Pearl, Angeles Alvarez Secord, David J. Peace, David G. Mutch, William T. Creasman, J. Julie Kim
Article
Oncology
Carol Aghajanian, Virginia Filiaci, Don S. Dizon, Jay W. Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu S. Tewari, David P. Bender, David M. O'Malley, Ashley Stuckey, Jianjiong Gao, Fanny Dao, Robert A. Soslow, Heather A. Lankes, Kathleen Moore, Douglas A. Levine
GYNECOLOGIC ONCOLOGY
(2018)
Article
Oncology
Jennifer L. Moss, Jeanne Murphy, Virginia L. Filiaci, Lari B. Wenzel, Lori Minasian, Sarah M. Temkin
SUPPORTIVE CARE IN CANCER
(2019)
Meeting Abstract
Oncology
Ursula A. Matulonis, Virginia L. Filiaci, Helen Q. Huang, Marcus Randall, Byoung Kim, Paul DiSilvestro, Katherine M. Moxley, David M. O'Malley, Matthew A. Powell, Nicola M. Spirtos, Krishnansu Sujata Tewari, William Richards, John Nakayama, Margaret Steinhoff, David Gardner Mutch, David S. Miller, Lari B. Wenzel, Daniela Matei
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Jennifer L. Moss, Jeanne Murphy, Virginia L. Filiaci, Lari B. Wenzel, Lori M. Minasian, Sarah Madhu Temkin
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Article
Oncology
Marcus E. Randall, Virginia Filiaci, D. Scott McMeekin, Vivian von Gruenigen, Helen Huang, Catheryn M. Yashar, Robert S. Mannel, Jae-Weon Kim, Ritu Salani, Paul A. DiSilvestro, James J. Burke, Thomas Rutherford, Nick M. Spirtos, Keith Terada, Penny R. Anderson, Wendy R. Brewster, William Small, Carol A. Aghajanian, David S. Miller
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Meeting Abstract
Oncology
Matthew A. Powell, Virginia L. Filiaci, Martee Leigh Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu Sujata Tewari, Larry J. Copeland, Angeles Alvarez Secord, David G. Mutch, Alessandro Santin, William Richards, David Philip Warshal, Nicola M. Spirtos, Paul Disilverstro, Olga Ioffe, David S. Miller
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Medicine, General & Internal
Daniela Matei, Virginia Filiaci, Marcus E. Randall, David Mutch, Margaret M. Steinhoff, Paul A. DiSilvestro, Katherine M. Moxley, Yong M. Kim, Matthew A. Powell, David M. O'Malley, Nick M. Spirtos, William Small, Krishnansu S. Tewari, William E. Richards, John Nakayama, Ursula A. Matulonis, Helen Q. Huang, David S. Miller
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Article
Oncology
David Scott Miller, Marcus E. Randall, Virginia Filiaci
GYNECOLOGIC ONCOLOGY
(2020)
Review
Oncology
Julian C. Schink, Virginia Filiaci, Helen Q. Huang, John Tidy, Matthew Winter, Jeanne Carter, Nancy Anderson, Katherine Moxley, Akira Yabuno, Sarah E. Taylor, Christina Kushnir, Neil Horowitz, David S. Miller
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
David S. Miller, Virginia L. Filiaci, Robert S. Mannel, David E. Cohn, Takashi Matsumoto, Krishnansu S. Tewari, Paul DiSilvestro, Michael L. Pearl, Peter A. Argenta, Matthew A. Powell, Susan L. Zweizig, David P. Warshal, Parviz Hanjani, Michael E. Carney, Helen Huang, David Cella, Richard Zaino, Gini F. Fleming
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Linda R. Duska, Virginia L. Filiaci, Joan L. Walker, Laura L. Holman, Emily K. Hill, Richard G. Moore, Kari L. Ring, Michael L. Pearl, Carolyn Y. Muller, Christina L. Kushnir, Heather A. Lankes, Megan Samuelson, Kelley S. Carrick, Anand Rajan, William H. Rodgers, Elise C. Kohn, Richard Piekarz, Kimberly K. Leslie
Summary: This study evaluated the short-term effects of MPA alone versus MPA plus entinostat on regulating progesterone receptor in women with newly diagnosed endometrioid endometrial adenocarcinoma. Although no immediate impact on PR was observed with entinostat in this short-term study, combination therapy showed better results in reducing Ki-67 levels. Lessons learned from this trial can help guide future treatment studies.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Matthew A. Powell, Virginia L. Filiaci, Martee L. Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu S. Tewari, Larry J. Copeland, Angeles A. Secord, David G. Mutch, Alessandro Santin, David P. Warshal, Nick M. Spirtos, Paul A. DiSilvestro, Olga B. Ioffe, David S. Miller
Summary: This phase III randomized trial compared the efficacy of paclitaxel and carboplatin (PC) with paclitaxel and ifosfamide (PI) in the treatment of uterine carcinosarcoma. The results showed that PC was not inferior to PI and should be considered as the standard treatment for uterine carcinosarcoma.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kristina W. Thiel, Eric J. Devor, Virginia L. Filiaci, David Mutch, Katherine Moxley, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Carol Aghajanian, Megan Samuelson, Heather A. Lankes, Robert A. Soslow, Kimberly K. Leslie
Summary: This study examined the association between p53 immunohistochemistry (IHC) and sequencing, and found that p53 IHC alone or integrated with TP53 sequencing can predict treatment outcomes. It was discovered that bevacizumab combined with chemotherapy is particularly beneficial for improving outcomes in a specific high-risk tumor genotype/phenotype identified by p53 IHC and TP53 sequencing.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Obstetrics & Gynecology
Alessandro D. Santin, Virginia Filiaci, Stefania Bellone, Elena S. Ratner, Cara A. Mathews, Guilherme Cantuaria, Camille C. Gunderson, Teresa Rutledge, Barbara M. Buttin, Heather A. Lankes, Michael Frumovitz, Samir N. Khleif, Warner K. Huh, Michael J. Birrer
GYNECOLOGIC ONCOLOGY REPORTS
(2020)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)